Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
FiercePharma4h
Merck joins American Lung Association in raising awareness of pulmonary arterial hypertension
As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...
Reuters14h
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck, which previously predicted 2024 sales between 20.7 billion ... is the world’s largest multimedia news provider, ...
The Pharma Letter2h
Merck & Co wades into PD-1/VEGF space via deal with LaNova Medicines
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
FierceBiotech2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck published phase 3 data on Tuesday. Investigators in China, Europe and North America randomized 94 people with TGCT to ...
Yale Daily News17h
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
Bindra and Herzon will also remain as consultants for Merck. According to Bindra, the Modifi Bio team met with Merck in ...
The Pharma Letter3h
Merck KGaA shares slip on cautious outlook
Merck, which previously predicted 2024 sales of between 20. ... useful and valuable Life Sciences service that brings ...
FiercePharma1d
AstraZeneca and Merck's Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings
NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...
Mena FN13h
New Campaign Aims To Improve Early Diagnosis And Treatment For People Living With Pulmonary Arterial Hypertension
The new PAH Awareness campaign by the American Lung Association, with support from Merck, aims to raise awareness about the symptoms of PAH to help at-risk individuals receive a prompt and accurate ...
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial
Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in ...
Business Wire8d
Merck to Participate in the UBS Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...